Ultracarbon300 mg

Established / Approved Uses

• Emergency treatment of acute oral poisoning or drug overdose: Ultracarbon is used in emergency medical settings to reduce absorption of many ingested drugs and toxins from the gastrointestinal tract. It is most effective when given within 1 hour of ingestion and must be administered under medical supervision.

OTC / Symptomatic Use

• Relief of gas, bloating, and flatulence: Lower-dose over-the-counter formulations of Ultracarbon are used for symptomatic relief of intestinal gas and associated discomfort.

Ultracarbon is not effective for all types of poisoning; it does not adsorb certain substances (see Contraindications and Precautions).

Medicinal Charcoal contains activated charcoal (activated carbon) as its active ingredient, a fine, odorless black powder produced by processing carbon-rich material (such as wood, coconut shell, or peat) at high temperature to create a highly porous adsorptive surface.

Medicinal Charcoal is available in different strengths and forms, including oral powder for suspension, aqueous suspension, and tablets/capsules (mainly for OTC gas-relief use). Emergency poisoning-management formulations are typically higher-strength aqueous suspensions or powders for suspension intended for supervised administration.

Ultracarbon is a non-absorbable adsorbent agent used both as an emergency antidote in acute poisoning and, in lower-dose forms, as a symptomatic remedy for intestinal gas. It works by physically binding (adsorbing) toxins, drugs, and gas within the gastrointestinal lumen rather than being absorbed into the bloodstream itself.

Ultracarbon has been used in medicine for many decades and remains a standard tool in poison-control and emergency-department management of selected oral overdoses, alongside its long-standing OTC use for digestive gas relief.

Antidotes / Gastrointestinal Adsorbents

Mechanism of Action

Medicinal Charcoal works by physical adsorption: its large, porous surface area binds drug and toxin molecules within the gastrointestinal tract, trapping them and preventing or reducing their systemic absorption. The bound complex is then eliminated in the stool. Medicinal Charcoal is not systemically absorbed itself and exerts no pharmacological action outside the gut lumen.

In its lower-dose OTC form, the same adsorptive property is used to bind intestinal gas bubbles, which is thought to reduce bloating, cramping, and flatulence, although evidence for this indication is more limited than for its use in poisoning.

For poisoning emergencies, Ultracarbon is administered orally or via nasogastric/orogastric tube as an aqueous slurry, only in a hospital or emergency setting under trained supervision, after the airway is assessed as protected.

For OTC gas relief, Ultracarbon is taken by mouth with a full glass of water, generally after meals and at bedtime. Ultracarbon should be separated by at least 2 hours from other oral medications, since it can reduce their absorption (see Interactions).

Ultracarbon can adsorb and reduce the absorption of many concurrently administered oral medications, potentially lowering their effectiveness. This is a physical interaction that applies broadly, not to one specific drug class. To minimize this risk, other oral medicines should be taken at least 2 hours before or after Ultracarbon whenever possible, and this separation is especially important during long-term or repeated OTC use.

Ultracarbon may also reduce the efficacy of orally administered antidotes or ipecac given for the same poisoning episode; sequencing of emergency treatments should be directed by the treating physician.

• Very common (expected, generally harmless): black-colored stools, mild constipation.
• Common: nausea, vomiting, abdominal discomfort.
• Uncommon but serious: aspiration of Ultracarbon into the lungs if vomiting occurs (particularly with impaired consciousness), intestinal obstruction or pseudo-obstruction with repeated/high doses, especially in patients with reduced gut motility.

Ultracarbon is not systemically absorbed, so systemic fetal or infant exposure is not expected; however, formal controlled studies in pregnancy and lactation are limited. For emergency poisoning indications, Ultracarbon should be used if clearly needed, since the benefit of treating a maternal overdose typically outweighs any theoretical risk; a physician should always be consulted. For routine OTC gas-relief use during pregnancy or breastfeeding, use only if clearly needed and consult a physician or pharmacist first.

• Ultracarbon should only be given for poisoning emergencies after the airway is confirmed protected, due to aspiration risk if vomiting occurs.
• Ultracarbon is not effective against certain poisons, including alcohols (ethanol, methanol), iron, lithium, cyanide, strong acids/alkalis, and some heavy metals; do not rely on it for these exposures.
• Separate Ultracarbon from other oral medicines by at least 2 hours to avoid reduced drug absorption (see Interactions).
• Use with caution in patients with reduced bowel motility or bowel obstruction risk, due to the potential for charcoal-related intestinal obstruction with repeated dosing.
• Black stools and darkened stool color are expected and not a cause for concern.

Excessive or repeated dosing of Ultracarbon may lead to constipation, intestinal impaction, or bowel obstruction, particularly in patients with slowed gut motility. If bowel obstruction is suspected (severe abdominal pain, distension, inability to pass stool or gas), or if Ultracarbon has been aspirated into the airway, seek immediate medical attention or contact emergency services/poison control. Do not attempt to manage suspected obstruction or aspiration at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Ultracarbon is used in children for emergency poisoning management with weight-based dosing under medical/poison-control supervision (see Dosage and Administration). OTC gas-relief use of Ultracarbon in young children is generally not recommended without physician advice; safety and efficacy for OTC use below the age stated on the product label have not been established.

Elderly

No specific dose adjustment is established for elderly patients, but this group may be more prone to constipation and reduced gut motility, so use of Ultracarbon should be monitored accordingly.

Renal/Hepatic Impairment

No dose adjustment is required for renal or hepatic impairment, since Ultracarbon is not systemically absorbed and is not metabolized by the liver or excreted by the kidneys.

For acute poisoning, Ultracarbon is typically given as a single emergency dose (occasionally as short repeat dosing under specialist direction). For OTC gas-relief use, Ultracarbon is intended for short-term, as-needed use; if symptoms persist beyond a few days, a physician should be consulted rather than continuing Ultracarbon indefinitely.

Powder formulations of Ultracarbon intended for poisoning management are reconstituted by mixing with water (or another suitable diluent) to form an aqueous slurry immediately before administration, according to the product's labeled concentration; this must be prepared by trained personnel in an emergency care setting.

Antidote; Gastrointestinal Adsorbent; Antiflatulent (OTC use)

Medicinal Charcoal acts through physical adsorption rather than a pharmacological receptor mechanism: its porous surface binds drug/toxin molecules or intestinal gas within the gut lumen, preventing their absorption into the bloodstream (in poisoning) or reducing gas-related bloating (in OTC use). The bound material passes out of the body in the stool.

Ultracarbon is used in pediatric emergency poisoning management with weight-based dosing (approximately 0.5–1 g/kg body weight, or per local poison-control protocol), administered only under medical supervision. For OTC gas-relief use, Ultracarbon should be used in children only as directed by a physician or as specified on the product label for the child's age group; safety and efficacy of OTC Ultracarbon in infants and very young children have not been established, and a physician should be consulted before use in this population.